Company
AboutTeamImpact
Science
Development ModelFocus AreasPipeline
Partnering
Business ModelPartners
Proof
Case StudiesContact
Specialty Pharmaceutical R&D · United Kingdom & India

Known molecules. Differentiated by design.

Off Targets develops complex injectable, sterile, and advanced-delivery formulations from known molecules — engineering the kind of formulation complexity that creates real clinical and commercial differentiation, and real barriers to entry.

  • Formulation science
  • Regulatory execution
  • De-risked, capital-light development
KNOWN MOLECULE DIFFERENTIATED PRODUCT
Known molecule. Differentiated formulation. Real barrier to entry.
18
Active injectable programs
10+
Oral solid products developed
50+
People globally
4
Patents filed
2
Hubs: UK & India

Injectable figure reflects active pipeline programs across long-acting injectables, pre-filled syringes, ready-to-use, lyophilised and emulsion products. Oral solids reflects products developed to date.

Differentiation is engineered, not inherited. Any known molecule can become a differentiated product.
A

Reduced technical risk

By focusing on known molecules with defined regulatory pathways, we design out the largest sources of early-stage failure before development even begins.

B

Disciplined, capital-efficient execution

Rigorous product selection and stage-gated development keep capital focused only on products with real regulatory and commercial feasibility.

C

Formulation as differentiation

Complex injectables, long-acting and lipid-based delivery, lyophilisation, and other advanced dosage forms create genuine clinical and commercial barriers to entry.

Explore Off Targets

Everything a partner or investor needs, in one place.

Next step

Discuss a program, licence or collaboration.